Tag Archive for: ADC

GSK5764227: An Antibody-Drug Conjugate Targeting B7-H3 Enters Phase 1/2 Trial

/in , , , /by

GSK5764227 represents a promising advancement in treating metastatic castration-resistant prostate cancer (mCRPC). This antibody-drug conjugate targets B7-H3, a protein overexpressed on prostate cancer cells, delivering a topoisomerase I inhibitor payload directly to tumors while minimizing damage to healthy tissues. Early data from broader solid tumor studies show the drug’s monotherapy potential, with objective response rates […]

Read more

MHB048C: A New PSMA-Targeted Therapy for Advanced Solid Tumors

/in , , , /by

MHB048C is an investigational antibody–drug conjugate designed to target prostate‑specific membrane antigen (PSMA) on tumor cells and selectively deliver a DNA topoisomerase I–inhibiting cytotoxic payload. By combining a PSMA‑directed antibody with a potent payload, the drug aims to exploit the high and relatively restricted expression of this surface antigen in advanced prostate cancer and in […]

Read more

UPDATE: TD001 a New Potent ADC for Prostate Cancer Expressing PSMA Enters Phase 1/2

/in , , , /by

TD001, is an investigational antibody-drug conjugate directed against prostate-specific membrane antigen (PSMA), developed for the treatment of men with metastatic castration-resistant prostate cancer whose tumors express PSMA will start recruiting patients for its phase 1/2 clinical trial. Mechanistically, TD001 combines a monoclonal antibody directed against PSMA with a topoisomerase I inhibitor payload, exatecan, linked through […]

Read more

GenSci143: A Dual-Target ADC Emerging for Metastatic Prostate Cancer

/in , , /by

GenSci143 (aka GenSci-143) is a bispecific antibody-drug conjugate under development for metastatic castration-resistant prostate cancer (mCRPC) and other solid tumors. The construct targets B7-H3 (CD276) and PSMA simultaneously with a bispecific antibody, coupled via a stable, cleavable linker to a topoisomerase I inhibitor payload, aiming to improve tumor cell killing and bystander effects across heterogeneous […]

Read more

Phase 1/2 Trial for DS-3939a: A Novel TA-MUC1–Directed ADC for Advanced Prostate Cancer and Beyond

/in , , , /by
Read more

Trop-2: A Promising Therapeutic Target in Prostate Cancer

/in /by
Read more